Home » Galleon Pharmaceuticals Reports Positive Results From Phase I Study of GAL-021 for Treatment of Respiratory Depression
Galleon Pharmaceuticals Reports Positive Results From Phase I Study of GAL-021 for Treatment of Respiratory Depression
Galleon Pharmaceuticals announced that its investigational drug GAL-021 appeared to be safe and well tolerated and demonstrated dose-proportional pharmacokinetic effects on respiration in a Phase I clinical study of 30 healthy adults.
Enhanced Online News
Enhanced Online News
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May